HopeStage
Back to all studies
CompletedNCT05886582

Rotigotine added to behavioral support for cocaine use

About this title

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

Read the official source — NCT05886582
Medication studyAges 25–70United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 25 years to 70 years.

Listed locations
RichmondSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 11, 2023
Recruitment status
Completed
Enrollment listed in the registry
50
Sponsor
Virginia Commonwealth University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 25 Years to 70 Years
Official registry ID
NCT05886582
Official title
Show the full official title

Phase 2a Double-Blind Placebo-Controlled Trial of Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Richmond

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Virginia Commonwealth University, a university.

Did this study involve medication?

Yes. The study involved medication, including Rotigotine Transdermal System [Neupro] and Placebo.

Who was this study for?

Listed age limits: 25 years to 70 years.

Want to explore more studies?

Explore studies